A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

Epilepsia

Volumn 56, Issue 12, 2015, Pages 1890-1898

  Klein, Pavel ^a   Schiemann, Jimmy ^b   Sperling, Michael R ^c   Whitesides, John ^b   Liang, Wei ^b   Stalvey, Tracy ^b   Brandt, Christian ^d   Kwan, Patrick ^e,f  

^a Mid Atlantic Epilepsy and Sleep Center   (United States)

^b UCB PHARMA   (Belgium)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d EPILEPSY CENTER BETHEL   (Germany)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Brivaracetam; Efficacy; Focal epilepsy; Partial onset seizures; Phase 3; Safety tolerability

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; TOPIRAMATE; VALPROIC ACID; 2 PYRROLIDONE DERIVATIVE; 2-(2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE; ANTICONVULSIVE AGENT;

ADULT; AGED; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT DURATION; URINARY TRACT INFECTION; CLINICAL TRIAL; EPILEPSIES, PARTIAL; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 84950248367     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13212     Document Type: Article

References (19)

1. Ngugi AK, Bottomley C, Kleinschmidt I, et al., Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010; 51: 883-890.
2. Brodie MJ, Barry SJ, Bamagous GA, et al., Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012; 78: 1548-1554.
3. Kwan P, Brodie MJ,. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
4. Brodie MJ, Kwan P,. Newer drugs for focal epilepsy in adults. BMJ 2012; 344: e345.
5. Löscher W, Schmidt D,. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011; 52: 657-678.
6. Lynch BA, Lambeng N, Nocka K, et al., The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101: 9861-9866.
7. Kaminski RM, Matagne A, Leclercq K, et al., SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715-720.
8. Gillard M, Fuks B, Leclercq K, et al., Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 2011; 664: 36-44.
9. Matagne A, Margineanu D-G, Kenda B, et al., Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008; 154: 1662-1671.
10. Biton V, Berkovic SF, Abou-Khalil B, et al., Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014; 55: 57-66.
11. Ryvlin P, Werhahn KJ, Blaszczyk B, et al., Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014; 55: 47-56.
12. Kwan P, Trinka E, van Paesschen W, et al., Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014; 55: 38-46.
13. French JA, Baroldi P, Brittain ST, et al., Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand 2014; 129: 143-153.
14. Elger C, Halasz P, Maia J, et al., Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009; 50: 454-463.
15. Kenda BM, Matagne AC, Talaga PE, et al., Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004; 47: 530-549.
16. Xu T, Bajjalieh SM,. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 2001; 3: 691-698.
17. Crowder KM, Gunther JM, Jones TA, et al., Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 1999; 96: 15268-15273.
18. French JA, Costantini C, Brodsky A, et al., Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial. Neurology 2010; 75: 519-525.
19. van Paesschen W, Hirsch E, Johnson M, et al., Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013; 54: 89-97.